Clinical Trials Browser

Amyloidosis, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Basal Cell, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Glioblastoma, Carcinoma, Hepatocellular, Hodgkin Disease, Lung Neoplasms, Melanoma, Multiple Myeloma, Myelodysplastic Syndromes, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Endometrial Neoplasms, Lymphoma, Mantle-Cell

NCT03201965 2025-11-26

A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis

Phase 3 Completed

416 enrolled 28 charts 5 FDA

Plasma cell

Amyloidosis

NCT02641145 2025-11-14

MICA

Phase NA Recruiting

171 enrolled

Plasma cell

Immunoglobulin Light-chain Amyloidosis, Amyloidosis, Cardiomyopathies

NCT02909036 2025-10-10

Study of Captisol Enabled Melphalan and Pharmacokinetics for Patients With Multiple Myeloma or Light Chain Amyloidosis That Are Receiving an Autologous Transplant.

Phase 1 Active not recruiting

46 enrolled

Plasma cell

Amyloidosis, Multiple Myeloma

NCT07215494 2025-10-10

A Clinical Study on Minimal Residual Disease in Patients With Systemic Light Chain Amyloidosis

Phase NA Not yet recruiting

50 enrolled

Plasma cell

Immunoglobulin Light-chain Amyloidosis, Amyloidosis

NCT01864018 2025-07-24

Ixazomib With Cyclophosphamide and Dexamethasone in Patients With Previously Untreated Symptomatic Multiple Myeloma or Light Chain Amyloidosis

Phase 1/2 Completed

87 enrolled 13 charts

Plasma cell

Amyloidosis, Multiple Myeloma

NCT06097832 2025-07-10

NEXICART-2

Phase 1/2 Recruiting

40 enrolled

Plasma cell

Immunoglobulin Light-chain Amyloidosis, Amyloidosis

Clinical Trials

Novel Imaging Tools in Newly-diagnosed Patients With Cardiac AL Amyloidosis

A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis

ALACRITY

ALANIS

Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis

Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)

The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas

A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis

MICA

Study of Captisol Enabled Melphalan and Pharmacokinetics for Patients With Multiple Myeloma or Light Chain Amyloidosis That Are Receiving an Autologous Transplant.

A Clinical Study on Minimal Residual Disease in Patients With Systemic Light Chain Amyloidosis

Ixazomib With Cyclophosphamide and Dexamethasone in Patients With Previously Untreated Symptomatic Multiple Myeloma or Light Chain Amyloidosis

NEXICART-2